GlobeNewswire: Histogen Inc Contains the last 10 of 78 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T00:47:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/12/14/2796714/0/en/Histogen-Announces-Second-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=59800Histogen Announces Second Adjournment of Special Meeting of Stockholders2023-12-14T21:15:00Z<![CDATA[Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PTPotential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved]]>Histogen Special Meeting QR CodeHistogen Special Meeting QR Codehttps://www.globenewswire.com/news-release/2023/12/05/2791342/0/en/Histogen-Announces-Adjournment-of-Special-Meeting-of-Stockholders.html?f=22&fvtc=4&fvtv=59800Histogen Announces Adjournment of Special Meeting of Stockholders2023-12-05T21:05:00Z<![CDATA[Meeting Adjourned to December 14, 2023 at 8:00 a.m. PT Meeting Adjourned to December 14, 2023 at 8:00 a.m. PT]]>Histogen Special Meeting QR CodeHistogen Special Meeting QR Codehttps://www.globenewswire.com/news-release/2023/09/18/2745181/0/en/Histogen-Announces-Board-Approval-of-Complete-Liquidation-and-Dissolution.html?f=22&fvtc=4&fvtv=59800Histogen Announces Board Approval of Complete Liquidation and Dissolution2023-09-18T20:05:04Z<![CDATA[SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include the distribution of remaining cash to stockholders following an orderly wind down of the company’s operations, including any proceeds from the potential sale of any pipeline assets. In order to reduce costs and in connection with the Plan of Dissolution, the company has discontinued all clinical development programs and reduced its workforce, including the anticipated termination of most employees by the end of September.]]>https://www.globenewswire.com/news-release/2023/07/05/2699923/0/en/Histogen-to-Explore-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=59800Histogen to Explore Strategic Alternatives2023-07-05T20:05:00Z<![CDATA[SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function, today announced that it has completed a review of its business, including the status of programs, resources and capabilities, and has decided to pause further development of its programs and commence a process to explore strategic alternatives with the intent to enhance shareholder value. Histogen has engaged Roth Capital Partners, LLC, to act as a strategic advisor in this process.]]>https://www.globenewswire.com/news-release/2023/05/11/2667286/0/en/Histogen-Reports-First-Quarter-2023-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=59800Histogen Reports First Quarter 2023 Results and Provides Business Update2023-05-11T20:05:00Z<![CDATA[Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)]]>https://www.globenewswire.com/news-release/2023/04/20/2651578/0/en/Histogen-Announces-Online-Publication-in-the-Journal-of-Investigative-Dermatology.html?f=22&fvtc=4&fvtv=59800Histogen Announces Online Publication in the Journal of Investigative Dermatology2023-04-20T20:15:17Z<![CDATA[Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice]]>https://www.globenewswire.com/news-release/2023/04/03/2640152/0/en/Histogen-Announces-Exclusive-Intellectual-Property-License-Agreement-with-Johns-Hopkins-University.html?f=22&fvtc=4&fvtv=59800Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University2023-04-03T20:05:38Z<![CDATA[Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan]]>https://www.globenewswire.com/news-release/2023/03/16/2629180/0/en/Histogen-Announces-Issuance-of-US-Patent-Covering-CTS-2090-Methods-of-Use.html?f=22&fvtc=4&fvtv=59800Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use2023-03-16T20:05:00Z<![CDATA[The Newly Issued Patent is Expected to Provide Protection into 2040]]>https://www.globenewswire.com/news-release/2023/03/09/2624567/0/en/Histogen-Reports-Year-End-2022-Results-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=59800Histogen Reports Year-End 2022 Results and Provides Business Update2023-03-09T21:05:00Z<![CDATA[Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases]]>https://www.globenewswire.com/news-release/2023/02/27/2616515/0/en/Histogen-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=59800Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)2023-02-27T21:15:00Z<![CDATA[SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments for infectious and inflammatory diseases and has a pipeline of restorative therapeutics for orthopedic indications, today announced the Board of Directors, upon the recommendation of the Company’s Compensation Committee granted Alfred J. Spada, the company’s recently appointed Executive Vice President and Chief Scientific Officer, a nonqualified stock option to purchase 106,793 shares of Histogen Inc. common stock with an exercise price of $1.04 based on the closing price on February 23, 2023, the grant date of the award. This grant was made as an inducement material to Dr. Spada’s acceptance of employment with Histogen and was approved by the Compensation Committee of Histogen’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).]]>